Detailed Narrative
Strong Q1 FY27 Performance Driven by Pharma Intermediates
Acutaas Chemicals reported robust financial results for Q1 FY27, with revenue from operations growing 59.1% year-on-year to INR 329.7 crores. This growth was primarily fueled by the Advanced Pharmaceutical Intermediates segment, which saw a 76.5% year-on-year increase in revenue to INR 292.7 crores. Gross profit rose 73% to INR 190.9 crores, leading to a 466 basis points expansion in gross margin to 57.9%.
Significant Profitability Expansion Across Key Metrics
The company achieved a more than twofold increase in EBITDA, reaching INR 113.1 crores, with the EBITDA margin expanding by 973 basis points year-on-year to 34.3%. Net profit after tax (PAT) also saw substantial growth, up 70.4% year-on-year to INR 74.9 crores, resulting in a PAT margin of 22.7%, an expansion of 151 basis points. Management attributed this strong profitability to higher gross margins and operational efficiencies.
Battery Chemicals Commercialization and Semiconductor Progress
Acutaas successfully completed the trial run of its battery chemicals plant and commenced commercial supply, noting unprecedented🌐 demand and tight global supply. The company expects a rapid ramp-up in this segment over the coming quarters and aims for full capacity utilization within three years. For semiconductor chemicals, the Indichem plant construction is ahead of schedule, with capex expected to be completed by the end of Q1 FY27, and revenue generation anticipated from FY28.
Strategic Shift in Specialty Chemicals Segment
The Specialty Chemicals segment experienced a 10.6% year-on-year revenue decline to INR 37 crores in Q1 FY27. This was a result of the company's strategic decision to gradually phase out lower-margin commodity chemicals and replace them with newer, higher-margin products. Despite the current decline, management does not expect the overall Specialty Chemical business to decline for the full financial year, anticipating growth from battery chemicals and new specialty products to offset the commodity phase-out.
Capital Expenditure and Future Expansion Plans
Capital expenditure for Q1 FY27 stood at INR 56 crores, with INR 15 crores allocated to the Indichem site and INR 41 crores to the ACL site, primarily for the battery chemical project, pilot plant, and maintenance. The company also plans additional capex for a new R&D center and land acquisition for future capacity expansion, particularly for the Pharma Intermediate business where the Sachin plant is at 83% capacity utilization and the Ankleshwar plant is expected to fill up in three years.
FY27 Guidance and Long-Term Outlook
Management reiterated its confidence in achieving 25% revenue growth for the full FY27, with stable margins similar to FY26. They also guided for approximately INR 150 crores in employee costs and similar other expenses for the year. For the CDMO business, the company targets INR 1,000 crores in revenue and expects validated products to contribute INR 50-100 crores each at peak, starting from H2 FY27. The revenue mix is expected to shift, with Pharma Intermediates' contribution decreasing from 87% to around 80% in the next three years.
Employee Recognition and Responsible Care Certification
Acutaas was certified as a 'Great Place to Work,' reflecting its culture of trust, collaboration, and pride among employees. Additionally, the company received the Responsible Care certification from the Indian Chemical Council, reaffirming its commitment to high standards of safety, health, and environmental performance. These recognitions underscore the company's focus on its people and sustainable operations.